Radiopharm Theranostics (RDPTF) Net Margin (2024 - 2026)
Radiopharm Theranostics' (RDPTF) quarterly Net Margin came in at 293.49% in Q2 2026, up 5600934.0% year-over-year from N/an in Q2 2025, and up 99.48% quarter-over-quarter from 56302.83% in Q2 2025.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Net Margin (2024 - 2026) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Net Margin for 3 consecutive years, with 293.49% the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn | -20,152.98% |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | -293.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -293.49% |
| Jun 30, 2025 | -56,302.83% |
| Jun 30, 2024 | -111.24% |